UnitedHealth Group (UNH) Stock Today, November 25, 2025: Price Surge, Reddit Buzz and New Red Flags for Investors

UnitedHealth Group Incorporated (NYSE: UNH) is back in the green today, but the story behind the move is far more complicated than a simple bounce.

As of the latest afternoon trading on November 25, 2025, UnitedHealth shares are changing hands around $327.7, up roughly 2.7% on the session from yesterday’s close near $319.1. ^[1] The stock is helping lift the Dow Jones Industrial Average, even as technology names drag on the broader S&P 500 — MarketWatch specifically notes Merck and UnitedHealth as key supports for the index today. ^[2]

Yet despite today’s pop, UNH remains a bruised giant: the stock is still about 35–36% lower year-to-date and roughly 47–49% below its 52‑week high above $620. ^[3]

Below is a breakdown of today’s price action, fresh November 25 news, and the bigger story investors will be watching.

UnitedHealth (UNH) Stock Price Today, 25 November 2025

Last close (24 Nov 2025): $319.05
Today’s open: $321.12
Intraday range so far: roughly $318.5 – $327.9
Recent price: about $327.7, up $8.7 on the day (~2.7%)
Volume: just over 2.8 million shares traded mid-session.

Over a longer horizon, the picture looks much harsher:

12‑month total return: about ‑46% (including dividends). ^[4]
Year-to-date 2025: down around 35–36%, while the S&P 500 is up mid‑teens. ^[5]
52‑week high:$622.83 on December 4, 2024
52‑week low:$234.60 on August 1, 2025
Current level: roughly 47% below the high, but about 40% above the low. ^[6]

UNH remains a mega‑cap with a market value near $290 billion, but the rerating from former “must‑own compounder” to “troubled turnaround” has been dramatic. ^[7]

Why UnitedHealth Is in the Spotlight Today

1. Lifting the Dow While Tech Cools

A MarketWatch live market update notes that “Tech stocks weigh on the S&P 500, [while] the Dow [is] lifted by Merck and UnitedHealth.” ^[8]

In practice, that means:

Health‑care names, including UNH, are acting as defensive ballast on a choppy day.
UnitedHealth’s roughly 2–3% gain is contributing a meaningful number of points to the price‑weighted Dow, even though the overall index move looks modest. ^[9]

For short‑term traders, this keeps UNH firmly in the “index driver” conversation again, after weeks in which its declines had been dragging the Dow the other way.

2. Reddit’s New Favorite Non‑Tech Stock

A new InsiderMonkey story today, “Is UnitedHealth Group (UNH) The Best Non‑Tech Stock to Buy? Reddit Says Yes,” highlights that UNH has become one of Reddit investors’ top non‑AI, non‑tech picks. ^[10]

Key points from that piece:

Redditors are crowding into “boring” mega‑caps they think can benefit if an AI/tech bubble pops.
UNH is down about 35% in 2025, yet many retail investors see this as a long‑term buying opportunity, not a death knell. ^[11]
The article emphasizes that Berkshire Hathaway holds roughly 5 million UNH shares, reinforcing the “Buffett stamp of approval” narrative. ^[12]

This Reddit enthusiasm stands in stark contrast to the institutional de‑risking we saw earlier this year when major hedge funds such as Michael Burry’s Scion Asset Management exited their UNH stakes following the initial earnings shock. ^[13]

3. Congressional Buying Resurfaces in the Headlines

MarketBeat’s UNH news feed today again flags Rep. Lisa C. McClain (R‑MI) as a notable buyer of UnitedHealth stock. ^[14]

While the actual purchase took place in August and was disclosed in September, the renewed November 25 coverage underscores:

Ongoing congressional interest in major health‑care names, including UNH.
The perception among some policymakers that UNH’s drawdown may represent value rather than structural decline. ^[15]

This kind of political‑trading headline often has more sentiment value than fundamental significance, but it adds to today’s narrative of “smart money nibbling” into the weakness.

New Research Today: Underperformance, Hybrid Care – and “Hidden Dangers”

Several fresh pieces of analysis dropped today, painting a nuanced picture of UNH’s risk/reward.

1. Still Underperforming the Nasdaq

A Barchart column titled “Is UnitedHealth Group Stock Underperforming the Nasdaq?” points out that:

UNH shares are 48.6% below their 52‑week high of $622.83.
The stock is up 4.9% over the last three months, but that still trails the Nasdaq Composite’s roughly 6.3% gain. ^[16]

The article emphasizes that UNH remains a mega‑cap anchor in health care but now trades with a much more cyclical, headline‑driven profile, instead of its old “steady compounder” reputation. ^[17]

2. Zacks on UNH’s “Hybrid Care” Strategy

Zacks published a note today asking, “Is UNH’s Hybrid Care Strategy Reshaping the Health System Playbook?” ^[18]

Key takeaways:

UnitedHealth is leaning hard into a “hybrid” model of care — blending in‑person, virtual and home‑based services through its Optum platforms and the UnitedHealthcare insurance arm.
Zacks highlights that UNH trades at a forward P/E near 18.3, noticeably above the managed‑care industry average around 15, suggesting the market still ascribes a premium for its scale and integrated model. ^[19]

In other words: the stock is cheaper than it used to be, but not obviously “distressed” on earnings multiples — which matters when earnings themselves have become less predictable.

3. Trefis: “The Hidden Dangers Facing UnitedHealth Stock”

Trefis published a cautionary analysis today bluntly titled “The Hidden Dangers Facing UnitedHealth Stock.” ^[20]

Their key arguments:

Historically, UNH has seen sharp drawdowns of more than 30% in under two months on more than one occasion — a reminder that volatility is not new for this name. ^[21]
On fundamentals, Trefis notes:
- LTM revenue growth ~10.5%, above the broader market’s ~6% range.
- A 3‑year average revenue growth of ~11.4%, versus around 5–6% for the market.
- Free cash flow margins near 4% and operating margin around 6.1%. ^[22]
Yet the stock trades at only ~16–17× earnings, down from the mid‑20s multiples it enjoyed when earnings growth looked bulletproof. ^[23]

The piece essentially argues that valuation looks reasonable on paper, but earnings risk remains elevated, so the lower multiple may be warranted.

The MCR Crisis: Explaining UNH’s 2025 Stock Crash

To understand why UNH is still down so heavily despite some good news, you have to look at the Medical Care Ratio (MCR) saga.

A Trefis deep‑dive published yesterday, “Why UnitedHealth Stock Dropped 50%: The MCR Crisis Explained,” lays out the damage in two phases. ^[24]

Phase 1: Earnings Got Crushed

UnitedHealth’s consolidated MCR — the percentage of premium dollars paid out in medical claims — climbed from around 82% in 2022 to roughly 88–90% by late 2025, with some quarters hitting 89.9%. ^[25]
That spike reflects much higher‑than‑expected utilization, particularly among Medicare Advantage members, where seniors used more outpatient and physician services than planned. ^[26]
Management was forced to slash 2025 adjusted EPS guidance from roughly $29.5–$30.0 down to at least $16.25 — more than $13 per share of expected earnings wiped out. ^[27]

Phase 2: The Valuation Multiple Collapsed

In its glory days, UNH commanded a P/E of about 24–26× because investors viewed its earnings as steady and high‑quality.
As earnings fell and uncertainty spiked, the multiple compressed to about 16–17×, effectively doubling the hit from the EPS cut. ^[28]

The bottom line: the stock price crash from above $600 to the low $300s is the product of both weaker earnings and a permanently more skeptical market — at least for now.

Fundamentals and Corporate Actions Behind Today’s Move

Q3 2025 Results and Guidance

On October 28, UnitedHealth reported Q3 2025 results that were better than Wall Street feared:

Revenue: $113.2 billion, up 12% year‑on‑year.
GAAP EPS: $2.59; adjusted EPS: $2.92, beating analyst estimates in the high‑$2.70s. ^[29]
MCR: 89.9%, still elevated but roughly in line with the company’s revised expectations. ^[30]
Operating cash flow: $5.9 billion, about 2.3× net income, underscoring still‑strong cash generation. ^[31]

Crucially, management raised its full‑year 2025 outlook to:

At least $14.90 in GAAP EPS
At least $16.25 in adjusted EPS ^[32]

Those numbers are far below the original 2025 plan, but they also signal that the worst of the surprise cost surge may be passing — one reason the stock has stabilized in the low‑to‑mid‑$300s over the past month.

Dividend and Yield

On November 7, UnitedHealth’s board authorized another quarterly dividend of $2.21 per share, or $8.84 annualized. ^[33]

At today’s price near $328, that implies a forward dividend yield of roughly 2.7% — noticeably higher than in prior years, thanks largely to the share price collapse rather than huge dividend hikes. ^[34]

For long‑term income investors, that yield is one of the few silver linings of 2025’s drawdown.

Board Shake‑Up: Scott Gottlieb Joins

Last week, UnitedHealth announced that Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration, has joined its Board of Directors as an independent director. ^[35]

Analysts and policy watchers see the move as:

A bid to strengthen regulatory expertise on the board amid scrutiny over Medicare Advantage billing and market power. ^[36]
A sign that UnitedHealth is trying to rebuild trust with regulators, investors and the broader health‑care ecosystem after a year of controversy.

Optum Rx and Operational Moves

Operationally, the company continues to tweak its Optum businesses:

On November 24, UnitedHealth’s Optum Rx unit announced changes to streamline pharmacy prior authorization, including removing many reauthorization requirements and expanding automation. ^[37]
A follow‑up report today notes that Optum Rx will eliminate reauthorization requirements for 40 more drugs starting January 1, 2026, aiming to speed patient access and reduce administrative friction. ^[38]

At the same time, Optum is shrinking in some areas. WARN filings show that Optum Health plans to lay off 572 employees in New Jersey and exit certain behavioral‑health services in the state in early 2026, reflecting ongoing restructuring under cost pressure. ^[39]

Structural and Regulatory Risks Still Loom Large

Even with today’s bounce, several medium‑term risks are front and center:

Payment disparities and antitrust scrutiny: Academic research using newly available price‑transparency data finds that UnitedHealthcare pays Optum physicians about 17% more on average than non‑Optum providers in the same markets — and up to 61% more where UnitedHealthcare’s market share is high. ^[40]
- That differential may attract further attention from regulators and lawmakers, especially given UNH’s size and vertical integration.
Optum under pressure: Optum Health’s operating margin has shrunk dramatically as value‑based care arrangements absorb the same utilization spikes hitting the insurance book, eroding the “growth engine” that once offset insurance volatility. ^[41]
Medicare Advantage reset: UnitedHealth is actively exiting some low‑margin Medicare Advantage segments, even dropping around a million seniors from certain products as it tries to reset profitability. ^[42]

All of this explains why, even after a strong Q3 beat and raised guidance, Wall Street is far more cautious on the stock than it was a year ago.

How Wall Street Sees UNH After Today’s News

Despite the drawdown, analyst sentiment is not outright bearish:

Data aggregated by MarketBeat show a “Moderate Buy” consensus rating on UNH, based on a mix of Buy, Hold and a handful of Sell recommendations. ^[43]
The average 12‑month price target is around $395–$400, implying low‑to‑mid‑20% upside from current levels — but with clearly elevated risk around 2026–2027 earnings. ^[44]
Trefis pegs fair value near $380, also suggesting upside, but stresses that a durable recovery requires both MCR stabilization and an Optum rebound, not just “less bad” headlines. ^[45]

In short, today’s positive price move and bullish retail chatter sit alongside sober institutional analysis that still views UNH as a high‑beta turnaround, not a simple value play.

What Today Means for Investors

For anyone following UnitedHealth on November 25, 2025, the key messages from today’s news flow are:

The stock is bouncing, but from a very deep hole. Up ~2–3% today, still down roughly 35% this year and almost half off its highs. ^[46]
Retail investors remain surprisingly optimistic. Reddit and some long‑only funds see a multi‑year recovery story in a dominant franchise that they believe over‑corrected. ^[47]
Professional research is split between “opportunity” and “warning sign.”
- Zacks and parts of Wall Street highlight the strength of UNH’s hybrid care model and long‑term demand tailwinds. ^[48]
- Trefis and other skeptics focus on the MCR shock, Optum margin compression and regulatory overhangs that could keep the multiple depressed for years. ^[49]

For potential investors, the practical implications are:

This is no longer a “set it and forget it” blue chip. UNH now trades more like a cyclical, policy‑sensitive healthcare name than an untouchable compounder.
The upside case rests on:
- Medical utilization normalizing,
- 2026 premium pricing restoring margins, and
- Optum returning to double‑digit earnings growth. ^[50]
The downside risk is that elevated MCR, regulatory constraints, or mis‑priced Medicare Advantage products persist longer than expected, making today’s seemingly modest 16–18× multiple not cheap at all. ^[51]